Lung cancer is the leading cause of cancer death among men and women in the world. Fewer than 15% achieve a 5-year survival. The vast majority (85%) present with advanced disease, although stage I patients may have a 5-year survival approaching 70%. R0 resection remains the standard treatment of choice for patients with clinical stages IA, IB, IIA, and non-T3N0 stage IIB NSCLC. Some controversies exist regarding the choice of procedure and technique that will meet surgical oncologic principles: conservative resection as a definitive alternative to lobectomy or pneumonectomy, or segmental resection, SBRT and so on.